NO942299D0 - Stabilisert, farmasöytisk preparat som omfatter veksthormon og asparagin - Google Patents

Stabilisert, farmasöytisk preparat som omfatter veksthormon og asparagin

Info

Publication number
NO942299D0
NO942299D0 NO942299A NO942299A NO942299D0 NO 942299 D0 NO942299 D0 NO 942299D0 NO 942299 A NO942299 A NO 942299A NO 942299 A NO942299 A NO 942299A NO 942299 D0 NO942299 D0 NO 942299D0
Authority
NO
Norway
Prior art keywords
growth hormone
asparagine
pharmaceutical preparation
stabilized pharmaceutical
dissolved
Prior art date
Application number
NO942299A
Other languages
English (en)
Norwegian (no)
Other versions
NO942299L (no
Inventor
Hans Holmegaard Soerensen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO942299L publication Critical patent/NO942299L/no
Publication of NO942299D0 publication Critical patent/NO942299D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
NO942299A 1991-12-20 1994-06-17 Stabilisert, farmasöytisk preparat som omfatter veksthormon og asparagin NO942299D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK912047A DK204791D0 (da) 1991-12-20 1991-12-20 Hidtil ukendt farmaceutisk praeparat
PCT/DK1992/000378 WO1993012811A1 (en) 1991-12-20 1992-12-16 A stabilized pharmaceutical formulation comprising growth hormone and asparagine

Publications (2)

Publication Number Publication Date
NO942299L NO942299L (no) 1994-06-17
NO942299D0 true NO942299D0 (no) 1994-06-17

Family

ID=8109696

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942299A NO942299D0 (no) 1991-12-20 1994-06-17 Stabilisert, farmasöytisk preparat som omfatter veksthormon og asparagin

Country Status (19)

Country Link
US (2) US5977069A (de)
EP (1) EP0618806B1 (de)
JP (1) JP3662580B2 (de)
KR (1) KR100270726B1 (de)
AT (1) ATE177645T1 (de)
AU (1) AU664416B2 (de)
BG (1) BG98804A (de)
CA (1) CA2125856A1 (de)
CZ (1) CZ282826B6 (de)
DE (1) DE69228704T2 (de)
DK (1) DK204791D0 (de)
FI (1) FI942905A0 (de)
HU (1) HUT69682A (de)
NO (1) NO942299D0 (de)
NZ (1) NZ246555A (de)
RO (1) RO112086B1 (de)
RU (1) RU2098130C1 (de)
SK (1) SK73794A3 (de)
WO (1) WO1993012811A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US6022858A (en) * 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
US5652216A (en) * 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
US5631225A (en) * 1994-10-13 1997-05-20 Novo Nordisk A/S Pharmaceutical formulation
ZA96122B (en) * 1995-01-13 1996-07-24 Novo Nordisk As A pharmaceutical formulation
US5705482A (en) * 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
EP0805689A1 (de) * 1995-01-13 1997-11-12 Novo Nordisk A/S Stabilisierte pharmazeutische zubereitung, welche ein wachstumshormon und x-lys enthält
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation
PT831787E (pt) * 1995-06-07 2002-02-28 Alkermes Inc Composicao para libertacao sustentada da hormona de crescimento humano
ZA965367B (en) * 1995-07-12 1997-01-23 Novo Nordisk As A pharmaceutical formulation
US6008256A (en) * 1995-08-28 1999-12-28 Showa Yakuhin Kako Co., Ltd. Composition for local anesthesia
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
US20070179096A1 (en) 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
CA2418960A1 (en) * 2000-08-07 2002-02-14 Inhale Therapeutic Systems, Inc. Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
US7271150B2 (en) * 2001-05-14 2007-09-18 United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified growth hormone
RU2234945C2 (ru) * 2002-10-15 2004-08-27 Вардосанидзе Ирина Викторовна Стабилизатор водного раствора и водосодержащего сырья с самопроизвольно изменяющимися окислительно-восстановительными свойствами
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
WO2008073856A2 (en) * 2006-12-08 2008-06-19 Massachusetts Institute Of Technology Delivery of nanoparticles and/or agents to cells
US20160015789A1 (en) * 2014-07-17 2016-01-21 Teva Pharmaceutical Industries, Ltd. FORMULATIONS OF AN ALBUMIN hGH FUSION PROTEIN

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4917685A (en) * 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
EP0303746B2 (de) * 1987-08-21 1998-12-02 Mallinckrodt Group Inc. Stabilisierung von Wachstumshormonen
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5122512A (en) * 1988-09-12 1992-06-16 Pitman-Moore, Inc. Swine growth promoting composition
EP0374120A3 (de) * 1988-12-13 1991-07-31 Monsanto Company Zusammensetzung mit kontrollierter Wirkstoffabgabe von Polypeptiden
DE69232847T2 (de) * 1991-12-20 2003-09-11 Novo Nordisk A/S, Bagsvaerd Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
DK0955062T3 (da) * 1992-07-31 2007-09-17 Genentech Inc Vandig formulering indeholdende humant væksthormon
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation

Also Published As

Publication number Publication date
HUT69682A (en) 1995-09-28
CZ282826B6 (cs) 1997-10-15
NZ246555A (en) 1996-03-26
DE69228704T2 (de) 1999-09-16
NO942299L (no) 1994-06-17
BG98804A (bg) 1995-02-28
HU9401831D0 (en) 1994-09-28
DE69228704D1 (de) 1999-04-22
KR100270726B1 (ko) 2000-11-01
RU2098130C1 (ru) 1997-12-10
KR940703689A (ko) 1994-12-12
DK204791D0 (da) 1991-12-20
RU94045921A (ru) 1996-08-27
FI942905A7 (fi) 1994-06-17
FI942905L (fi) 1994-06-17
ATE177645T1 (de) 1999-04-15
EP0618806A1 (de) 1994-10-12
FI942905A0 (fi) 1994-06-17
EP0618806B1 (de) 1999-03-17
CA2125856A1 (en) 1993-07-08
US5851992A (en) 1998-12-22
AU664416B2 (en) 1995-11-16
WO1993012811A1 (en) 1993-07-08
US5977069A (en) 1999-11-02
RO112086B1 (ro) 1997-05-30
SK73794A3 (en) 1995-03-08
JPH07502515A (ja) 1995-03-16
AU3344593A (en) 1993-07-28
CZ145894A3 (en) 1994-12-15
JP3662580B2 (ja) 2005-06-22

Similar Documents

Publication Publication Date Title
NO942299D0 (no) Stabilisert, farmasöytisk preparat som omfatter veksthormon og asparagin
DK0618807T3 (da) Stabiliseret farmaceutisk formulering omfattende human væksthormon og histidin
DE69525955D1 (de) Ein wachstumshormon und isoleucin enthaltende pharmazeutische formulierung
PT785795E (pt) Composicao farmaceutica
ATE254928T1 (de) Stabilisierte zusammensetzung mit nootropen wirkstoffen
NO883926D0 (no) Fremgangsmaate for fremstilling av stabilisert humanproteinpreparat.
NO980155L (no) Stabilisert farmasöytisk preparat som omfatter et veksthormon som er forbehandlet med sink og eventuelt lysin eller kasiumioner
EP1197221A4 (de) LANGFRISTIG STABILISIERTE PRäPARATE
IL115592A (en) Stabilized pharmaceutical formulation comprising a growth hormone and leucine
NO980103L (no) Stabilisert farmasöytisk preparat som omfatter et veksthormon og et peptid omfattende minst én basisk aminosyrerest og minst én sur aminosyrerest